IONS Logo

Ionis Pharmaceuticals, Inc. (IONS) 

NASDAQ
Market Cap
$6.1B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
585 of 776
Rank in Industry
318 of 433

Largest Insider Buys in Sector

IONS Stock Price History Chart

IONS Stock Performance

About Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered …

Insider Activity of Ionis Pharmaceuticals, Inc.

Over the last 12 months, insiders at Ionis Pharmaceuticals, Inc. have bought $0 and sold $25.06M worth of Ionis Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Ionis Pharmaceuticals, Inc. have bought $0 and sold $12.92M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,000 shares for transaction amount of $12,520 was made by KLEIN JOSEPH III (director) on 2006‑08‑15.

List of Insider Buy and Sell Transactions, Ionis Pharmaceuticals, Inc.

2024-10-16SaleEVP Research
53
<0.0001%
$38.31$2,031-0.71%
2024-08-29SaleEVP, Chief Development Officer
331
0.0002%
$49.63$16,428-20.48%
2024-08-28SaleEVP, Chief Development Officer
320
0.0002%
$49.16$15,731-19.40%
2024-08-05SaleEVP, Chief Development Officer
2,430
0.0017%
$48.00$116,640-11.00%
2024-07-16Saledirector
1,637
0.0012%
$49.49$81,019-14.21%
2024-07-16Saledirector
12,000
0.0086%
$50.00$600,000-14.21%
2024-06-17Saledirector
16,000
0.0111%
$40.29$644,640+7.26%
2024-05-03Saledirector
6,000
0.0042%
$42.71$256,277-2.82%
2024-04-16SaleEVP, Corp and Development Ops
905
0.0006%
$41.66$37,698-1.32%
2024-04-16SaleEVP, Chief Business Officer
4,006
0.0028%
$41.60$166,641-1.32%
2024-02-16SaleChief Executive Officer
387
0.0003%
$44.49$17,219-4.88%
2024-02-02SaleChief Executive Officer
23,907
0.0158%
$49.37$1.18M-14.57%
2024-02-02SaleEVP, Finance & CFO
2,162
0.0014%
$49.54$107,105-14.57%
2024-02-02SaleEVP, Chief Development Officer
1,995
0.0013%
$50.04$99,836-14.57%
2024-02-02SaleEVP, Chief Scientific Officer
1,885
0.0013%
$49.52$93,337-14.57%
2024-02-02SaleEVP CLO & General Counsel
1,995
0.0013%
$49.67$99,099-14.57%
2024-02-02SaleEVP, Chf Clinical Develop Ofcr
2,106
0.0014%
$49.59$104,437-14.57%
2024-02-02SaleEVP,Chf GL Pdt Str & Oper Ofc
2,162
0.0014%
$49.60$107,240-14.57%
2024-02-02SaleEVP Research
1,940
0.0013%
$49.56$96,149-14.57%
2024-01-31SaleEVP Research
10,773
0.0075%
$52.00$560,196-17.16%

Insider Historical Profitability

49.6%
KLEIN JOSEPH IIIdirector
0
0%
$38.68935+49.6%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$947.75M14.9821.86M+1.59%+$14.82M0.06
The Vanguard Group$582.21M9.213.43M-5.44%-$33.51M0.01
T Rowe Price Investment Management Inc$577.3M9.1213.32M+0.88%+$5.01M0.35
BlackRock$423.61M6.79.77M+7.89%+$30.97M0.01
Bellevue Group$359.78M5.698.3M-4.76%-$17.97M5.52
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.